Immunogenicity and protection of octavalent influenza vaccine candidates using adjuvanted proteins or mRNA-LNPs in naïve mice

1. Yamanouchi, T., Sakakami, K. & Iwashima, S. The infecting agent in influenza: an experimental research. The Lancet 193, 971 (1919).

   Google Scholar 

2. Lebailly, C. N. C. Quelques notions expérimentales sur le virus de la grippe [Certain experimental ideas about the infectious agent of influenza]. C. R. Acad. Sci. 167, 607–610 (1918).

   Google Scholar 

3. Taubenberger, J. K., Hultin, J. V. & Morens, D. M. Discovery and characterization of the 1918 pandemic influenza virus in historical context. Antivir. Ther. 12, 581–591 (2007).

   Google Scholar 

4. Burnet, F. M. Influenza virus infections of the chick embryo lung. Br. J. Exp. Pathol. 21, 147–153 (1940).

   Google Scholar 

5. Stanley, W. M. The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J. Exp. Med. 81, 193–218 (1945).

   Google Scholar 

6. Trombetta, C. M., Kistner, O., Montomoli, E., Viviani, S. & Marchi, S. Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines. Vaccines (Basel) 10, 714 (2022).

   Google Scholar 

7. Guo, J. et al. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: a systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine 42, 1883–1891 (2024).

   Google Scholar 

8. Rose, A. M. C. et al. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Influenza Other Respir. Viruses 18, e13255 (2024).

   Google Scholar 

9. Kim DeLuca, E. et al. Cost-effectiveness of routine annual influenza vaccination by age and risk status. Vaccine 41, 4239–4248 (2023).

   Google Scholar 

10. Waterlow, N. R. et al. The potential cost-effectiveness of next generation influenza vaccines in England and Wales: a modelling analysis. Vaccine 41, 6017–6024 (2023).

    Google Scholar 

11. Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429.e10 (2018).

    Google Scholar 

12. Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383–397 (2019).

    Google Scholar 

13. de Vries, E., Du, W., Guo, H. & de Haan, C. A. M. Influenza A virus hemagglutinin–neuraminidase–receptor balance: preserving virus motility. Trends Microbiol. 28, 57–67 (2020).

    Google Scholar 

14. Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A. & Klenk, H.-D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78, 12665–12667 (2004).

    Google Scholar 

15. Palese, P., Tobita, K., Ueda, M. & Compans, R. W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61, 397–410 (1974).

    Google Scholar 

16. Monto, A. rnoldS. & Kendal, A. lanP. Effect of neuraminidase antibody on Hong Kong. Lancet 301, 623–625 (1973).

    Google Scholar 

17. Murphy, B. R., Kasel, J. A. & Chanock, R. M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. New Engl. J. Med. 286, 1329–1332 (1972).

    Google Scholar 

18. Couch, R. B., Kasel, J. A., Gerin, J. L., Schulman, J. L. & Kilbourne, E. D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 129, 411–420 (1974).

    Google Scholar 

19. Rosu, M. E. et al. Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model. J. Virol. 96, e0195921 (2022).

    Google Scholar 

20. Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191–1199 (2015).

    Google Scholar 

21. Memoli, M. J. et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. mBio 7, e00417-16 (2016).

    Google Scholar 

22. Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, e02332-17 (2018).

23. Cox, M. M. J., Izikson, R., Post, P. & Dunkle, L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther. Adv. Vaccines 3, 97 (2015).

    Google Scholar 

24. Fiers, W., Neirynck, S., Deroo, T., Saelens, X. & Jou, W. M. Soluble recombinant influenza vaccines. Philos. Trans. R. Soc. Lond. Ser. B: Biol. Sci. 356, 1961–1963 (2001).

    Google Scholar 

25. Sultana, I. et al. Stability of neuraminidase in inactivated influenza vaccines. Vaccine 32, 2225–2230 (2014).

    Google Scholar 

26. Strohmeier, S. et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. mBio 12, e0224121 (2021).

    Google Scholar 

27. Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines 6, 153 (2021).

    Google Scholar 

28. Catani, J. P. P. et al. Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase. npj Vaccines 7, 1–9 (2022).

    Google Scholar 

29. Schmidt, P. M., Attwood, R. M., Mohr, P. G., Barrett, S. A. & McKimm-Breschkin, J. L. A Generic system for the expression and purification of soluble and stable influenza Neuraminidase. PLoS ONE 6, e16284–e16284 (2011).

    Google Scholar 

30. Karikó, K., Muramatsu, H., Keller, J. M. & Weissman, D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther. 20, 948–953 (2012).

    Google Scholar 

31. Zhang, H. et al. Deep generative models design mRNA sequences with enhanced translational capacity and stability. Science 390, eadr8470 (2025).

32. Stadler, C. R. et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell—engaging bispecific antibody targeting human claudin 6. Sci. Transl. Med. 16, eadl2720 (2024).

    Google Scholar 

33. Goodwin, E., Gibbs, J. S., Yewdell, J. W., Eisenlohr, L. C. & Hensley, S. E. Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice. J. Virol. 98, e00766-24 (2024).

    Google Scholar 

34. Willis, E. et al. Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Sci. Transl. Med. 12, eaav5701 (2020).

    Google Scholar 

35. Leonard, R. A. et al. Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA. Nat. Commun. 15, 8712 (2024).

    Google Scholar 

36. Stacey, H. et al. Leveraging pre-vaccination antibody titres across multiple influenza H3N2 variants to forecast the post-vaccination response. eBioMedicine 116, https://doi.org/10.1016/j.ebiom.2025.105744 (2025).

37. Magnusson, S. E. et al. Immune enhancing properties of the novel Matrix-M^TM adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 31, 1725–1733 (2013).

    Google Scholar 

38. Rudicell, R. S. et al. Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine 37, 6208–6220 (2019).

    Google Scholar 

39. McElhaney, J. E. et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect. Dis. 13, 485–496 (2013).

    Google Scholar 

40. Ustyugova, I. V. et al. AF03 adjuvant improves anti-hemagglutinin and anti-neuraminidase immune responses induced by licensed seasonal quadrivalent influenza vaccines in mice. Vaccine 41, 2022–2034 (2023).

    Google Scholar 

41. Cox, M. M. J. & Karl Anderson, D. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respir. Viruses 1, 35–40 (2007).

    Google Scholar 

42. Marsh, G. & Tannock, G. The role of reverse genetics in the development of vaccines against respiratory viruses. Expert Opin. Biol. Ther. 5, 369–380 (2005).

    Google Scholar 

43. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 97, 6108–6113 (2000).

    Google Scholar 

44. McCullers, J. A., Hoffmann, E., Huber, V. C. & Nickerson, A. D. A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. Virology 336, 318–326 (2005).

    Google Scholar 

45. Job, E. R. et al. Antibodies directed toward neuraminidase N1 control disease in a mouse model of influenza. J. Virol. 92, https://doi.org/10.1128/JVI.01584-17 (2018).

46. Caillet, C. et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 28, 3076–3079 (2010).

    Google Scholar 

Download references